S
Shanghai Yuesai Biotechnology
Developing cell therapy drugs based on stem cell technology
About Shanghai Yuesai Biotechnology
Unixell is an innovative pharmaceutical company specializing in the development of next-generation cell therapy drugs. The company leverages a robust technology platform that includes unique reprogramming technology, stem cell separation, high-precision genetic editing, and autonomous research and development for tracking the SASCR spectrum. Unixell primarily focuses on treating neurodegenerative diseases, rare diseases, and tumors. The company collaborates with healthcare institutions like Reginald Hospital to advance treatments such as Parkinson's auto stem cell therapy. Unixell operates in the biopharmaceutical market, serving healthcare providers and patients who require advanced therapeutic solutions. The business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary cell therapy drugs. Revenue is generated through partnerships, licensing agreements, and the sale of its therapeutic products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 22.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Spinout, Biotech and Pharma, Rare Diseases, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2026 | $6.9M | $69M | Pan-Lin Asset Management | ↗ |
| SERIES A✓Equity / VC | Apr 2024 | $14M | $55M | Pudong Venture Capital | ↗ |
Growth signals
Latest recorded traffic for Shanghai Yuesai Biotechnology is 2K monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Yuesai Biotechnology in its local ecosystem
The Shanghai Yuesai Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- PCPudong Venture Capital
Pan-Lin Asset Management
Other known investors1 additional known investor
Chinese Academy Of Sciences
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Yuesai Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Yuesai Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









